Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent.

ABSTRACT:

Objectives

This final report from the REMEDEE Registry assessed the long-term safety and efficacy of the dual-therapy COMBO stent in a large unselected patient population.

Background

The bio-engineered COMBO stent (OrbusNeich Medical BV, The Netherlands) is a dual-therapy pro-healing stent. Data of long-term safety and efficacy of the this stent is lacking.

Methods

The prospective, multicenter, investigator-initiated REMEDEE Registry evaluated clinical outcomes after COMBO stent implantation in daily clinical practice. One thousand patients were enrolled between June 2013 and March 2014.

Results

Five-year follow-up data were obtained in 97.2% of patients. At 5-years, target lesion failure (TLF) (composite of cardiac death, target-vessel myocardial infarction, o

SUBMITTER: Kerkmeijer LSM 

PROVIDER: S-EPMC8518525 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature